This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 40893 results found since Jan 2013.
Knockdown of neurotrophin receptor-interacting melanoma-associated antigen homolog inhibits acute myeloid leukemia cell growth via the ERK pathway
In this study, NRAGE was identified as a tumor promoter in AML, which had an effect on cell proliferation, cell survival, and cell cycle through the ERK signaling pathway in AML cells.PMID:37635487 | DOI:10.4103/cjop.CJOP-D-22-00162
Source: The Chinese Journal of Physiology - August 28, 2023 Category: Physiology Authors: Hongxia Zhang Guangsheng Wu Beili Chen Source Type: research
Therapeutic strategies and promising vaccine for hepatitis C virus infection
AbstractHepatitis C virus (HCV) infection is still a significant global health problem despite therapeutic advancements. Ribavirin and interferon therapy have been the sole available treatments for HCV infection for a number of years with low efficacy. Thus, currently, a number of therapeutic strategies are being used, including nanoparticles (NPs), micro-RNAs such as small interfering RNA (siRNA), RNAi-based gene silencing and antisense oligonucleotide-based microRNA-122, microRNA-155, and short hairpin RNAs (shRNAs), and immunotherapeutic approaches such as anti-programmed cell death 1(PD-1), monoclonal antibodies (mAb Â...
Source: Immunity, Inflammation and Disease - August 28, 2023 Category: Allergy & Immunology Authors: Adane Adugna Tags: REVIEW ARTICLE Source Type: research
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation
ConclusionsThe consistency of patisiran PK and PD between patients with and without LT suggests that neither LT nor concomitantly administered immunosuppressants influence hepatic uptake or RNAi activity of patisiran. The patisiran dosing regimen of 0.3 mg/kg q3w is appropriate for hATTR amyloidosis patients with or without LT.Clinical Trial Registration NoNCT03862807.
Source: Clinical Pharmacokinetics - August 28, 2023 Category: Drugs & Pharmacology Source Type: research
Cytochrome P450 26A1 Contributes to the Maintenance of Neuropathic Pain
AbstractThe cytochrome P450 proteins (CYP450s) have been implicated in catalyzing numerous important biological reactions and contribute to a variety of diseases. CYP26A1, a member of the CYP450 family, carries out the oxidative metabolism of retinoic acid (RA), the active metabolite of vitamin A. Here we report that CYP26A1 was dramatically upregulated in the spinal cord after spinal nerve ligation (SNL). CYP26A1 was mainly expressed in spinal neurons and astrocytes. HPLC analysis displayed that the content of all-trans-RA (at-RA), the substrate of CYP26A1, was reduced in the spinal cord on day 7 after SNL. Inhibition of ...
Source: Neuroscience Bulletin - August 28, 2023 Category: Neuroscience Source Type: research
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation
ConclusionsThe consistency of patisiran PK and PD between patients with and without LT suggests that neither LT nor concomitantly administered immunosuppressants influence hepatic uptake or RNAi activity of patisiran. The patisiran dosing regimen of 0.3 mg/kg q3w is appropriate for hATTR amyloidosis patients with or without LT.Clinical Trial Registration NoNCT03862807.
Source: Clinical Pharmacokinetics - August 28, 2023 Category: Drugs & Pharmacology Source Type: research
Lnc-Malat1 promotes slow myofiber-type transformation through sponging miR-129-5p in C2C12 myotubes
In this study, knockdown of lnc-Malat1 by siRNA significantly inhibited the expression of myoblast marker genes (MyHC, MyoD, and MyoG) and slow muscle fiber marker genes (MyHC I), together with repressed expression of mitochondria-related genes COX5A, ACADM, CPTA1, FABP3, and NDUFA1. Overexpression of lnc-Malat1 exerted an opposite effect, promoting myoblast differentiation and slow muscle fiber formation. Dual luciferase reporter assay revealed a direct interaction between lnc-Malat1 and miR-129-5p, and overexpression of lnc-Malat1 significantly inhibited miR-129-5p expression, thereby elevating the expression of Mef2a, m...
Source: Cell Research - August 27, 2023 Category: Cytology Authors: Yongqi Yue Yuhe Wang Chenglong Wen Yingying Meng Ying Peng Xiao Li Source Type: research
Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy
Int J Biol Macromol. 2023 Aug 25:126539. doi: 10.1016/j.ijbiomac.2023.126539. Online ahead of print.ABSTRACTCancer immunotherapy is the most promising method for tumor therapy in recent years, among which the macrophages play a critical role in the antitumor immune response. However, tumor-associated macrophages (TAMs) usually display the tumor-promoting M2 phenotype rather than the tumor-killing M1 phenotype. Moreover, the over-expressed CD47 on tumor cells severely hinders the function of macrophages by blocking the CD47/SIRPα pathway. Herein, a nano-assembly system of CHTR/siRNA was constructed through the host-guest i...
Source: International Journal of Biological Macromolecules - August 27, 2023 Category: Biochemistry Authors: Tongyi Shang Xinying Yu Yuan Gu Rong Du Yanjun Cai Yuwei Li Guodong Zheng Chaoqun Wang Jian Zhang Jifang Liu Shisong Han Bin Yang Source Type: research
GSE241418 Transcriptomic and Translatomic Analyses Reveal Insights into the Signaling Pathways of the Innate Immune Response in the Spleens of SPF Chickens Infected with Avian Reovirus
This study not only provides a new perspective on the regulatory mechanisms of the innate immune response after ARV infection but also enriches the knowledge of the host defense mechanisms against ARV invasion and the outcome of ARV evasion of the host innate immune response.
Source: GEO: Gene Expression Omnibus - August 27, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Other Gallus gallus Source Type: research
New and future therapies: Changes in the therapeutic armamentarium for SLE
Best Pract Res Clin Rheumatol. 2023 Aug 24:101865. doi: 10.1016/j.berh.2023.101865. Online ahead of print.ABSTRACTFollowing better understanding of molecular pathways involved in the pathogenesis of Systemic lupus erythematosus (SLE), pharmaceutical companies have been investigating new targeted drugs for SLE. The purpose of this scoping review is to provide an updated view of the most promising targeted therapies currently in clinical development or recently approved for SLE treatment as well as of the most promising potential future therapeutic strategies in SLE. In the past several years, two new drugs have been develop...
Source: Cell Research - August 26, 2023 Category: Cytology Authors: Anca Askanase Leila Khalili Wei Tang Philippe Mertz Marc Scherlinger Eden Sebbag Fran çois Chasset Renaud Felten Laurent Arnaud Source Type: research
Musashi-2 binds with Fbxo6 to induce Rnaset2 ubiquitination and chemokine signaling pathway during vascular smooth muscle cell phenotypic switch in atherosclerosis
CONCLUSION: Our findings demonstrated that MSI2 could bind with Fbxo6 to induce Rnaset2 ubiquitination and the activation of chemokine signaling pathway during VSMC phenotypic switch in AS.PMID:37633478 | DOI:10.1016/j.cellsig.2023.110869
Source: Atherosclerosis - August 26, 2023 Category: Cardiology Authors: Tao Zhang Shusheng Wu Rongwei Xu Shuguang Zhang Minghai Wang Jie Li Source Type: research
